While marijuana is bred with the only purpose of maximizing its THC concentration, industrial hemp always has trace amounts of THC and naturally occurring high amounts of CBD (it has the highest CBD/THC ratio of all cannabis strains, even Cannabis ruderalis) This means that industrial hemp’s chemical profile makes it incapable of inducing intoxicating effects and getting you “high” from ingesting it.
In 2013 a CNN program that featured Charlotte's Web cannabis brought increased attention to the use of CBD in the treatment of seizure disorders. Since then, 16 states have passed laws to allow the use of CBD products with a doctor's recommendation (instead of a prescription) for treatment of certain medical conditions. This is in addition to the 30 states that have passed comprehensive medical cannabis laws, which allow for the use of cannabis products with no restrictions on THC content. Of these 30 states, eight have legalized the use and sale of cannabis products without requirement for a doctor's recommendation.
Cannabidiol is a chemical in the Cannabis sativa plant, also known as marijuana. Over 80 chemicals, known as cannabinoids, have been identified in the Cannabis sativa plant. While delta-9-tetrahydrocannabinol (THC) is the major active ingredient, cannabidiol makes up about 40% of cannabis extracts and has been studied for many different uses. According to the U.S. Food and Drug Administration (FDA), because cannabidiol has been studied as a new drug, products containing cannabidiol are not defined as dietary supplements. But there are still products labeled as dietary supplements on the market that contain cannabidiol. The amount of cannabidiol contained in these products is not always reported accurately on the product label.
In addition, some cannabinoids interact synergistically, producing unique effects that are not found when using them individually. For example, CBD inhibits THC’s psychotropic effects when the two are taken together. However, CBD does this (and produces many other effects) without directly interacting with the cannabinoid receptors. At first, scientists thought there was a third type of CB receptor just for Cannabidiol, but the answer was far more interesting and revealing.
In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.